MetaVia Inc.

MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel pharmaceuticals to address cardiometabolic diseases. Incorporated in Delaware in October 2014, the company aims to transform treatment paradigms within this therapeutic area.

The company's primary pipeline candidates include DA-1726, an oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist for the treatment of obesity, and vanoglipel (DA-1241), a G-protein-coupled receptor 119 (GPR119) agonist targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). MetaVia also maintains legacy therapeutic programs, such as ANA001, NB-01, NB-02, and Gemcabene, which address various viral, neurodegenerative, and cardiometabolic indications.

MetaVia Inc. is publicly traded on the Nasdaq Capital Market under the ticker symbol MTVA. Recent corporate activities include the dosing of the first patient in higher-dose Phase 1 studies for DA-1726 in April 2026 and the reporting of year-end 2025 financial results in March 2026. The company, led by President and CEO Hyung Heon Kim, operates as a subsidiary of Dong-A ST Co., Ltd., which holds a significant stake.